COMMUNIQUÉS West-GlobeNewswire

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
12/02/2026
AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31 [...]
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 [...]
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
12/02/2026
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
12/02/2026
2025 total revenue of $673 million, Crysvita ® revenue of $481 million and Dojolvi ® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a [...]
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
12/02/2026
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
12/02/2026
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous [...]
OKYO Pharma Announces Public Offering of Ordinary Shares
12/02/2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/02/2026
LEXINGTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
12/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
12/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). [...]
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
12/02/2026
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
12/02/2026
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, [...]
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
12/02/2026
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the [...]
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results
12/02/2026
MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results: Q4 2025 Q4 [...]
Northwestern Medicine and Founders Factory to scale European AI ventures into America’s leading health system
12/02/2026
AI is driving healthcare’s next wave: AI and deeptech advancements are transforming healthcare infrastructure, delivering novel approaches to safer, more efficient and more personalised patient care Advancing innovation [...]
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
12/02/2026
Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day. Date: Thursday, February 26 [...]
GENFIT va recevoir un paiement d’étape de 20 M$ suite au dépassement du seuil des 200 M$ de ventes nettes d’Iqirvo® par Ipsen dès sa première année complète de commercialisation
12/02/2026
Ventes nettes d’Iqirvo® dans la PBC par Ipsen atteignant 88 M$ au 4T25, portant le total annuel pour 2025 à 208 M$, déclenchant le premier paiement d’étape 1 commercial pour GENFIT plus tôt que prévu Confirmation par [...]
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
12/02/2026
Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule 1 Ipsen confirmed its commitment to launch a [...]

Pages